Met Life Investment Management, LLC Tg Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $18 Billion
  • Q4 2024

A detailed history of Met Life Investment Management, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 84,360 shares of TGTX stock, worth $2.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
84,360
Previous 80,608 4.65%
Holding current value
$2.9 Million
Previous $1.89 Million 34.69%
% of portfolio
0.01%
Previous 0.01%

Shares

49 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$21.31 - $35.09 $79,955 - $131,657
3,752 Added 4.65%
84,360 $2.54 Million
Q2 2024

Aug 13, 2024
BUY
$13.32 - $19.19 $110,369 - $159,008
8,286 Added 11.46%
80,608 $1.43 Million
Q1 2024

May 14, 2024
BUY
$13.02 - $21.3 $941,632 - $1.54 Million
72,322 New
72,322 $1.1 Million
Q3 2023

May 09, 2024
BUY
$8.36 - $26.5 $18,609 - $58,989
2,226 Added 3.18%
72,322 $604,000
Q2 2023

Apr 29, 2024
BUY
$15.48 - $35.0 $1.12 Million - $2.53 Million
72,322 New
72,322 $1.8 Million
Q2 2023

Aug 10, 2023
BUY
$15.48 - $35.0 $34,458 - $77,910
2,226 Added 3.18%
72,322 $1.8 Million
Q1 2023

May 09, 2024
BUY
$10.23 - $19.34 $717,082 - $1.36 Million
70,096 New
70,096 $1.05 Billion
Q3 2022

May 10, 2024
BUY
$4.57 - $8.4 $27,845 - $51,181
6,093 Added 9.52%
70,096 $414,000
Q3 2022

Mar 22, 2023
BUY
$4.57 - $8.4 $27,845 - $51,181
6,093 Added 9.52%
70,096 $414,000
Q3 2022

Nov 14, 2022
BUY
$4.57 - $8.4 $27,845 - $51,181
6,093 Added 9.52%
70,096 $415,000
Q2 2022

May 10, 2024
SELL
$3.74 - $10.66 $27,174 - $77,455
-7,266 Reduced 10.2%
64,003 $272,000
Q2 2022

Jun 20, 2023
SELL
$3.74 - $10.66 $22,787 - $64,951
-6,093 Reduced 8.69%
64,003 $272,000
Q2 2022

Mar 22, 2023
SELL
$3.74 - $10.66 $27,174 - $77,455
-7,266 Reduced 10.2%
64,003 $272,000
Q2 2022

Aug 11, 2022
SELL
$3.74 - $10.66 $27,174 - $77,455
-7,266 Reduced 10.2%
64,003 $272,000
Q1 2022

May 10, 2024
BUY
$7.81 - $20.45 $556,610 - $1.46 Million
71,269 New
71,269 $677,000
Q1 2022

Jun 20, 2023
BUY
$7.81 - $20.45 $9,161 - $23,987
1,173 Added 1.67%
71,269 $677,000
Q1 2022

Mar 22, 2023
BUY
$7.81 - $20.45 $206,519 - $540,759
26,443 Added 58.99%
71,269 $677,000
Q1 2022

May 12, 2022
BUY
$7.81 - $20.45 $206,519 - $540,759
26,443 Added 58.99%
71,269 $678,000
Q4 2021

Jun 21, 2023
SELL
$15.2 - $35.51 $384,104 - $897,337
-25,270 Reduced 36.05%
44,826 $851,000
Q3 2021

Jun 21, 2023
SELL
$21.78 - $40.45 $550,380 - $1.02 Million
-25,270 Reduced 36.05%
44,826 $1.49 Million
Q2 2021

Jun 21, 2023
SELL
$32.5 - $48.96 $821,275 - $1.24 Million
-25,270 Reduced 36.05%
44,826 $1.74 Million
Q1 2021

May 17, 2024
SELL
$41.61 - $54.3 $1.14 Million - $1.49 Million
-27,496 Reduced 38.02%
44,826 $2.16 Million
Q1 2021

Jun 26, 2023
SELL
$41.61 - $54.3 $1.05 Million - $1.37 Million
-25,270 Reduced 36.05%
44,826 $2.16 Billion
Q1 2021

Mar 22, 2023
SELL
$41.61 - $54.3 $84,759 - $110,609
-2,037 Reduced 4.35%
44,826 $2.16 Million
Q1 2021

May 14, 2021
SELL
$41.61 - $54.3 $84,759 - $110,609
-2,037 Reduced 4.35%
44,826 $2.16 Million
Q4 2020

Jun 22, 2023
SELL
$25.27 - $54.9 $587,097 - $1.28 Million
-23,233 Reduced 33.14%
46,863 $2.44 Million
Q3 2020

May 24, 2024
BUY
$18.49 - $27.24 $70,502 - $103,866
3,813 Added 8.86%
46,863 $1.25 Billion
Q3 2020

Jun 26, 2023
SELL
$18.49 - $27.24 $429,578 - $632,866
-23,233 Reduced 33.14%
46,863 $1.25 Million
Q3 2020

Mar 22, 2023
BUY
$18.49 - $27.24 $70,502 - $103,866
3,813 Added 8.86%
46,863 $1.25 Million
Q3 2020

Nov 13, 2020
BUY
$18.49 - $27.24 $70,502 - $103,866
3,813 Added 8.86%
46,863 $1.25 Million
Q2 2020

May 24, 2024
SELL
$8.9 - $21.84 $260,520 - $639,300
-29,272 Reduced 40.47%
43,050 $839 Million
Q2 2020

Jun 26, 2023
SELL
$8.9 - $21.84 $240,709 - $590,684
-27,046 Reduced 38.58%
43,050 $838,000
Q2 2020

Mar 22, 2023
BUY
$8.9 - $21.84 $47,445 - $116,429
5,331 Added 14.13%
43,050 $838,000
Q2 2020

Aug 14, 2020
BUY
$8.9 - $21.84 $47,445 - $116,429
5,331 Added 14.13%
43,050 $839,000
Q1 2020

Jul 12, 2023
SELL
$7.14 - $15.99 $231,171 - $517,708
-32,377 Reduced 46.19%
37,719 $371,000
Q4 2019

Jul 12, 2023
SELL
$5.1 - $11.2 $165,122 - $362,622
-32,377 Reduced 46.19%
37,719 $418,000
Q3 2019

Jul 12, 2023
SELL
$5.38 - $8.99 $174,188 - $291,069
-32,377 Reduced 46.19%
37,719 $211,000
Q3 2019

Mar 22, 2023
BUY
$5.38 - $8.99 $50,760 - $84,820
9,435 Added 33.36%
37,719 $211,000
Q3 2019

Nov 14, 2019
BUY
$5.38 - $8.99 $50,760 - $84,820
9,435 Added 33.36%
37,719 $212,000
Q2 2019

Jul 12, 2023
SELL
$6.27 - $8.65 $203,003 - $280,061
-32,377 Reduced 46.19%
37,719 $326,000
Q1 2019

Jul 13, 2023
SELL
$4.02 - $8.04 $168,084 - $336,168
-41,812 Reduced 59.65%
28,284 $227,000
Q4 2018

Jul 13, 2023
SELL
$3.44 - $5.76 $143,833 - $240,837
-41,812 Reduced 59.65%
28,284 $115,000
Q4 2018

Mar 22, 2023
SELL
$3.44 - $5.76 $53,664 - $89,856
-15,600 Reduced 35.55%
28,284 $115,000
Q4 2018

Feb 14, 2019
SELL
$3.44 - $5.76 $53,664 - $89,856
-15,600 Reduced 35.55%
28,284 $116,000
Q3 2018

Jul 13, 2023
SELL
$5.15 - $14.0 $215,331 - $585,368
-41,812 Reduced 59.65%
28,284 $158,000
Q3 2018

Mar 22, 2023
SELL
$5.15 - $14.0 $134,991 - $366,968
-26,212 Reduced 37.39%
43,884 $245,000
Q3 2018

Nov 14, 2018
BUY
$5.15 - $14.0 $80,340 - $218,400
15,600 Added 55.15%
43,884 $246,000
Q2 2018

Aug 15, 2018
BUY
$12.5 - $15.0 $91,975 - $110,370
7,358 Added 35.16%
28,284 $372,000
Q4 2017

Feb 15, 2018
BUY
$7.35 - $12.3 $153,806 - $257,389
20,926
20,926 $172,000

Others Institutions Holding TGTX

# of Institutions
372
Shares Held
85.5M
Call Options Held
3.78M
Put Options Held
3M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email